EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

The Characteristics and Outcomes in Patients with Acute Heart Failure Who Used Tolvaptan: From KCHF Registry

Ryusuke Nishikawa, Takao Kato, Takeshi Morimoto, Hidenori Yaku, Yasutaka Inuzuka, Yodo Tamaki, Erika Yamamoto, Neiko Ozasa, Tomohisa Tada, Hiroki Sakamoto, Yuta Seko, Masayuki Shiba und 18 weitere

ESC Heart Failure · 2023

DOI: 10.1002/ehf2.14494 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Ryusuke Nishikawa und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan. Hauptthemen laut MEDLINE: Tolvaptan, Heart Failure, Registries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The use of tolvaptan is increasing in clinical practice in Japan. However, the characteristics of patients who used tolvaptan and the timing of its use in patients with acute heart failure (AHF) are not fully elucidated. Methods and results Among consecutive 4056 patients in the Kyoto Congestive Heart Failure registry, we analysed 3802 patients after excluding patients on dialysis, prior or unknown tolvaptan use at admission, and unknown timing of tolvaptan use, and we divided them into two groups: tolvaptan use (N = 773) and no tolvaptan use (N = 3029). The prevalence of tolvaptan use varied widely from 48.7% to 0% across the participating centres. Factors independently associated with tolvaptan use were diabetes, poor medical adherence, oedema, pleural effusion, hyponatraemia, estimated glomerular filtration rate < 30 mL/min/1.73 m2, moderate/severe tricuspid regurgitation, dobutamine infusion within 24 h, and additional inotropes infusion beyond 24 h after admission. The mortality rate at 90 days after admission was significantly higher in the tolvaptan use group than in the no tolvaptan use group (14.3% vs. 8.6%, P = 0.049). However, after adjustment, the excess mortality risk of tolvaptan use relative to no tolvaptan use was no longer significant (hazard ratio = 1.53, 95% confidence interval = 0.77–3.02, P = 0.22). Patients with tolvaptan use had a longer hospital stay [median (interquartile range): 22 (15–34) days vs. 15 (11–21) days, P < 0.0001] and a higher prevalence of worsening renal failure (47.0% vs. 31.8%, P < 0.0001) and worsening heart failure (24.8% vs. 14.4%, P < 0.0001) than those without.

Conclusions

AHF patients with tolvaptan use had more congestive status with poorer in-hospital outcomes and higher short-term mortality than those without tolvaptan use. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT02334891 (NCT02334891) and https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017241 (UMIN000015238).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TolvaptanHeart FailureRegistriesHumansMaleFemaleAgedAntidiuretic Hormone Receptor AntagonistsAcute DiseaseJapanTreatment OutcomeRetrospective StudiesFollow-Up StudiesSurvival RateMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

Cohort studyHeart failureTolvaptan

Substanzen

TolvaptanAntidiuretic Hormone Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan.
  • Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.
  • Department of Cardiovascular Medicine, Shiga General Hospital, Moriyama, Japan.
  • Division of Cardiology, Tenri Hospital, Tenri, Japan.
  • Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan.
  • Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Nishikawa, R., Kato, T., Morimoto, T., Yaku, H., Inuzuka, Y., Tamaki, Y., Yamamoto, E., Ozasa, N., Tada, T., Sakamoto, H., Seko, Y., Shiba, M., Yoshikawa, Y., Yamashita, Y., Kitai, T., Taniguchi, R., Iguchi, M., Nagao, K., Kawai, T., …, & KCHF Study Investigators (2023). The Characteristics and Outcomes in Patients with Acute Heart Failure Who Used Tolvaptan: From KCHF Registry. ESC Heart Failure. https://doi.org/10.1002/ehf2.14494

Vancouver

Nishikawa R, Kato T, Morimoto T, Yaku H, Inuzuka Y, Tamaki Y, et al. The Characteristics and Outcomes in Patients with Acute Heart Failure Who Used Tolvaptan: From KCHF Registry. ESC Heart Failure. 2023. doi:10.1002/ehf2.14494

BibTeX
@article{Nishikawa2023,
  author = {Nishikawa, Ryusuke and Kato, Takao and Morimoto, Takeshi and Yaku, Hidenori and Inuzuka, Yasutaka and Tamaki, Yodo and Yamamoto, Erika and Ozasa, Neiko and Tada, Tomohisa and Sakamoto, Hiroki and Seko, Yuta and Shiba, Masayuki and Yoshikawa, Yusuke and Yamashita, Yugo and Kitai, Takeshi and Taniguchi, Ryoji and Iguchi, Moritake and Nagao, Kazuya and Kawai, Takafumi and Komasa, Akihiro and Kawase, Yuichi and Morinaga, Takashi and Toyofuku, Mamoru and Furukawa, Yutaka and Ando, Kenji and Kadota, Kazushige and Sato, Yukihito and Kuwahara, Koichiro and Kimura, Takeshi and KCHF Study Investigators, KCHF Study Investigators},
  title = {The Characteristics and Outcomes in Patients with Acute Heart Failure Who Used Tolvaptan: From KCHF Registry},
  journal = {ESC Heart Failure},
  year = {2023},
  doi = {10.1002/ehf2.14494}
}
Kostenlos starten →